US 11,773,165 B2
Markers of acute myeloid leukemia stem cells
Ravindra Majeti, Palo Alto, CA (US); and Irving L. Weissman, Stanford, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed by The Board of Trustees of the Leland Stanford Junior University, Standford, CA (US)
Filed on May 4, 2022, as Appl. No. 17/736,874.
Application 17/736,874 is a continuation of application No. 17/000,063, filed on Aug. 21, 2020.
Application 17/000,063 is a continuation of application No. 15/704,790, filed on Sep. 14, 2017, granted, now 10,662,242, issued on May 26, 2020.
Application 15/704,790 is a continuation of application No. 14/927,349, filed on Oct. 29, 2015, granted, now 9,796,781, issued on Oct. 24, 2017.
Application 14/927,349 is a continuation of application No. 14/164,009, filed on Jan. 24, 2014, granted, now 9,193,955, issued on Nov. 24, 2015.
Application 14/164,009 is a continuation of application No. 13/739,788, filed on Jan. 11, 2013, granted, now 8,709,429, issued on Apr. 29, 2014.
Application 13/739,788 is a continuation of application No. 12/836,152, filed on Jul. 14, 2010, granted, now 8,361,736, issued on Jan. 29, 2013.
Application 12/836,152 is a continuation in part of application No. PCT/US2009/000224, filed on Jan. 13, 2009.
Claims priority of provisional application 61/011,324, filed on Jan. 15, 2008.
Prior Publication US 2022/0324973 A1, Oct. 13, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61P 35/02 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12Q 1/6886 (2018.01); G01N 33/50 (2006.01); G01N 33/574 (2006.01); C12N 5/00 (2006.01); C12N 5/09 (2010.01); A61K 39/00 (2006.01)
CPC C07K 16/2803 (2013.01) [A61P 35/02 (2018.01); C07K 16/28 (2013.01); C07K 16/2896 (2013.01); C07K 16/30 (2013.01); C12N 5/0093 (2013.01); C12N 5/0694 (2013.01); C12Q 1/6886 (2013.01); G01N 33/5011 (2013.01); G01N 33/57426 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/24 (2013.01); C07K 2317/73 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/136 (2013.01); G01N 2500/04 (2013.01)] 33 Claims
 
1. A method for treating a human subject with acute myeloid leukemia (AML), the method comprising:
administering to the human subject an antibody or a fragment thereof that specifically binds to CD47 of an AML stem cell and prevents the CD47 from binding to a SIRPα receptor of a macrophage or a dendritic cell.